Risk factors, morbidity rates and long-term prognosis in benign hyperplasia and prostate cancer (literature review)-Reference-Cited by-同舟云学术

Risk factors, morbidity rates and long-term prognosis in benign hyperplasia and prostate cancer (literature review)

Published:2021-06-01 Issue:6 Volume: Page:24-33
ISSN:2074-9600
Container-title:Spravočnik vrača obŝej praktiki (Journal of Family Medicine)
language:ru
Short-container-title:

Author:

Perevezentsev Egor Aleksandrovich¹,Malykhina Anastasiya Sergeevna¹,Volodin Mark Albertovich¹,Volodin Denis Igorevich¹,Bolgov Evgeniy Nikolaevich¹

Affiliation:

1. Privolzhsky Research Medical University of the Ministry of Health of Russia

Abstract

Diseases of the urological profile are one of the most important medical and social issues of the modern world. According to various sources, from 50 % to 75 % of men over 50 years old have benign prostatic hyperplasia (BPH), and by the age of 80, BPH is detected in 90 % of the male population. BPH manifests itself with lower urinary tract symptoms (LUTS) in most patients. Prostate cancer ranks 2nd or 3rd in the structure of malignant neoplasms in men, and the prevalence of this pathology continues to grow. This trend is associated with an increase in average life expectancy, improved diagnosis of pathologies and early detection of the disease. Risk factors affecting the development of both prostate cancer and BPH include the patient’s age, race, family history, eating habits, the presence or absence of bad habits, and a sedentary lifestyle. Surgical methods for treating prostate cancer include open retropubic prostatectomy and laparoscopic adenomectomy. The «gold standard» of surgical treatment of BPH is transurethral resection of the prostate (TURP), but the emergence of new endovideosurgical methods (bipolar TURP, transurethral enucleation of the prostate (TUEP) allows to expand the scope of their use and reduce possible complications in the early and late postoperative period.

Publisher

PANORAMA Publishing House

Reference34 articles.

1. Al-Shukri S. Kh., Korneev I. A., Aloian K. A., Matveev A. V. Diagnostika i stadirovanie raka predstatelnoi zhelezy [Diagnosis and staging of prostate cancer] // Urologicheskie vedomosti [Urological Bulletin]. 2012. No. 4. P. 23–27. (In Russ.)

2. Bespalov V. G., Kuzhanov A. A., Vasilieva I. N., Semenov A. L., Aleksandrov V. A. Vzaimosviaz mezhdu dobrokachestvennoi giperplaziei i rakom predstatelnoi zhelezy: novye vozmozhnosti dlia khimioprofilaktiki raka prostaty [The relationship between benign hyperplasia and prostate cancer: new opportunities for chemoprophylaxis of prostate cancer] // Voprosy onkologii [Problems of oncology]. 2016. Vol. 62. No. 2. P. 360–371. (In Russ.)

3. Kirpatovskii V. I., Chochuev O. S., Nadtochii O. N., Frolova E. V., Kazachenko A. V., Sivkov A. V. Metabolicheskii sindrom: vliianie na progressirovanie DGPZh, simptomov nizhnikh mochevykh putei i effektivnost terapii DGPZh (obzor literatury) [Metabolic syndrome: influence on the progression of BPH, lower urinary tract symptoms and the effectiveness of BPH therapy (literature review)] // Eksperimentalnaia i klinicheskaia urologiia [Experimental and clinical urology]. 2017. No. 1. P. 74–83. (In Russ.)

4. Sevriukov F. A. Kompleksnoe izuchenie kachestva zhizni bolnykh s dobrokachestvennoi giperplaziei predstatelnoi zhelezy. Problemy standartizatsii v zdravookhranenii [Comprehensive study of the quality of life of patients with benign prostatic hyperplasia. Problems of standardization in healthcare]. 2012. No. 3–4. P. 54–55. (In Russ.)

5. Sevriukov F. A., Malinina O. Iu., Elina Iu. A. Osobennosti meditsinskogo obespecheniia patsientov s dobrokachestvennoi giperplaziei predstatelnoi zhelezy na etape ambulatorno-poliklinicheskoi pomoshchi [Features of medical support for patients with benign prostatic hyperplasia at the stage of outpatient care] // Meditsinskii almanakh [Medical almanac]. 2011. No. 1 (14). P. 25–27. (In Russ.)